Max Neeman
International is the only CRO in India to manage hemophilia trials according to
the Clinical Trials Registry-India (CTRI). Of the total hemophilia trials
currently being conducted in India, Max Neeman can boast supporting 80% of
these with the remaining conducted by pharma companies.
Max Neeman
International has established a team of experts specialized in carrying out
hemophilia trials in response to sponsor demand. The team has the required
expertise via involvement of academia with industry, hemophilia trial
experience and extensive database of best Investigators for indication to
develop innovative approaches to optimize complex study design. Often strict
inclusion/exclusion criteria and data analysis for such studies create the
greatest challenge for Biotech and Pharma that the company's expertise can
address.
Max Neeman is a
leading CRO in India that has a focus on hemophilia and bleeding disorder
studies, in addition to other indications. Patient enrollment for complex
global and multi-centric hemophilia trials is challenging because potential
subjects are fewer in number and widely dispersed. With an Incidence of 1 in
10,000 people, India has more than 120,000 hemophilic and thus it has evolved
into a preferred destination for conducting such trials because of low cost and
faster patient recruitment.
Source: PRNewswire
0 comments:
Post a Comment